BUILDING YOUR FIRST PEPTIDE STACK
The most common beginner mistake is running three compounds simultaneously and then having no idea what worked, what caused side effects, or what to repeat. A principled first stack is a single primary goal with a single primary compound — and a tracking system rigorous enough to tell you something actionable at the end.
1.The one-compound rule for beginners
The temptation when starting is to address everything at once: healing, body composition, sleep, cognition, fat loss. Resist this. Your first cycle should have one primary goal and one compound matched to that goal. If you run BPC-157 alone for 12 weeks and your knee improves significantly, you have learned that BPC-157 works for your knee. If you run BPC-157, ipamorelin, CJC-1295, and semaglutide simultaneously and feel better across the board, you have learned nothing useful about attribution.
The one-compound rule is not just about knowledge — it's about safety. When something unexpected happens (and something often does on any first cycle — an odd side effect, an unexpected change in sleep, a surprising emotional shift), you need to know what caused it. With one compound, attribution is clear. With four compounds, it is impossible.
Pick your primary goal with brutal honesty. Is it a specific injury you want to heal? Is it body composition — more muscle, less fat? Is it weight loss specifically? Is it cognitive performance or stress management? Each goal has a clear first-choice compound, and running that compound cleanly for one cycle produces genuine knowledge about how you respond.
After a full first cycle with documented, measured outcomes, you have earned the right to add a second compound. Your experience with the first compound gives you a baseline to detect changes attributable to the second. One new variable at a time is not just beginner advice — it is how anyone running multiple compounds over years maintains the ability to attribute effects and iterate intelligently.
2.The three proven beginner entry points
Entry point 1 — Healing: BPC-157 at 250-500 mcg subcutaneously once daily for 84 days (12 weeks). This is the simplest, safest, and most forgiving first cycle available. BPC-157 has an excellent safety profile, does not require specific timing windows, does not interact with common medications, and has the broadest indication spectrum — it works for soft tissue injuries, gut health, inflammation, and general healing. For a specific injury, inject near it; for systemic or gut applications, anywhere in the abdomen.
Entry point 2 — Body composition and recovery: CJC-1295 no DAC at 100-200 mcg combined with ipamorelin at 200-300 mcg, injected subcutaneously together before sleep in a fasted state, for 112 days (16 weeks). This combination is more synergistic than either compound alone. The first week's improved sleep confirms the protocol is working. Meaningful body composition changes take 8+ weeks. This is the most widely run beginner protocol for people whose primary goal is performance and body composition improvement.
Entry point 3 — Weight loss: semaglutide at 0.25 mg once weekly for 4 weeks, then 0.5 mg once weekly for 8+ weeks. This is the only entry point that does not require daily injections. Appetite suppression begins within the first week. GI adaptation takes 2-4 weeks. Weight loss accelerates through weeks 4-16 as caloric deficit compounds. This entry point requires the most attention to protein intake and resistance training to protect lean mass alongside fat loss.
Each of these entry points has years of both scientific literature and community user experience supporting them. They are not the only options — they are the highest-confidence starting points where the evidence base is strong, side effect profiles are understood, and the path to meaningful results in a reasonable timeframe is well-established.
What to avoid as a beginner: compounds with complex dosing requirements, narrow therapeutic windows, or limited community experience. Retatrutide (triple GLP-1/GIP/glucagon agonist) has a more complex escalation and side effect profile than semaglutide. Hexarelin (a potent GHRP) has more cortisol and prolactin side effects than ipamorelin. Melanotan II has complex effects and significant immediate side effects. Start with the most forgiving options first.
3.Designing your protocol before you start
Write out your protocol before ordering anything. Document: the compound(s) you are running, the dose, the injection timing, the cycle length, the expected results and when you expect them, and the metrics you will track. This planning step forces clarity and prevents impulsive mid-cycle changes.
Calculate your supply needs before purchasing. If you are running BPC-157 at 500 mcg once daily for 84 days, you need 42 mg of BPC-157 (84 days × 0.5 mg/day). Account for some waste from reconstitution. Order 45-50 mg to avoid running short. Running out mid-protocol and having to wait for a new order breaks protocol consistency and makes outcome assessment harder.
Plan your reconstitution ahead of time. Decide how many milligrams per vial you want in each reconstituted unit, calculate how much BAC water to add, and write this down so you do not have to recalculate at the time of reconstitution. Use the PepVault calculator for this — it handles the math and shows you the units per dose.
Set realistic outcome benchmarks. For the healing entry point: 'meaningful reduction in pain during squatting by week 8, near-complete resolution by week 12.' For the body composition entry point: 'improved sleep within 2 weeks, body weight within 2% of start at 8 weeks (water retention artifact), visible body composition improvement in photographs at 12 weeks.' For the GLP-1 entry point: 'significant appetite reduction by day 5, 4-6 lbs lost by week 4, 12-15 lbs lost by week 12.'
Identify your 'stop criteria' before starting: conditions under which you will stop the protocol immediately (severe allergic reaction, specific medical events, specific test results outside acceptable ranges) versus conditions where you will reduce dose and reassess versus conditions where you will push through a difficult period. Decision trees made in advance are more reliable than decisions made in the middle of discomfort or anxiety.
4.Adding a second compound after your first cycle
The timing for adding a second compound: after completing your first full cycle, taking the planned off-cycle break, and reviewing your outcomes data. Not mid-cycle, not because you read something exciting, not because your training partner is running something different.
Common second additions by first cycle type: BPC-157 graduates often add TB-500 to their next healing cycle for the synergistic soft tissue repair effect — TB-500 addresses cellular migration and actin regulation while BPC-157 addresses angiogenesis, and the combination outperforms either alone for complex soft tissue injuries. GH peptide graduates sometimes add a second daily injection (pre-morning instead of just pre-sleep) or add a GHRP-2 to the stack for stronger GH stimulation when more aggressive output is desired.
Stack building is iterative over multiple cycles, not a design exercise at the beginning. The person who runs three optimized beginner cycles has far more useful knowledge about their personal response to peptides than someone who jumps directly to a complex 5-compound stack after reading about it for two weeks.
When adding a second compound, run it for at least 4-6 weeks before drawing conclusions about what it is adding. Add it at the beginning of a new cycle (not mid-cycle) so you have the cleanest attribution possible. Maintain all the same tracking you were doing in your single-compound cycle.
What combinations to avoid early: running a GH peptide stack and a GLP-1 simultaneously as your first experience with either class. Both cause significant changes to appetite, body composition, energy, and GI function. Their combined effects make interpretation impossible. Run one for a full cycle first. Also avoid combining multiple GHRPs (GHRP-2 + GHRP-6 + ipamorelin) — receptor saturation means you are spending more for no additional GH output while multiplying side effects.
Sources & Studies
Bowers CY., J Clin Endocrinol Metab, 2001
Sigalos JT, Pastuszak AW., Sex Med Rev, 2018